301333.SHE R&G PharmaStudies Co. Ltd. A
- Market cap
- CNY 5.47B
- P/E
- 45.3x
- P/B
- 2.68x
- ROE
- 5.0%
- Dividend yield
- 0.22%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 301333.SHE undervalued?
Graham number301333.SHE trades 132.2% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
R&G PharmaStudies Co. Ltd. A fundamental analysis
No fundamental analysis for R&G PharmaStudies Co. Ltd. A yet.
R&G PharmaStudies Co. Ltd. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About R&G PharmaStudies Co. Ltd. A
R&G PharmaStudies Co., Ltd. operates as a clinical trial outsourcing service provider in China and internationally. It offers drug clinical research and development integrated services. The company's services include clinical trial operation, clinical trial site management, biological sample testing, data management and statistical analysis, clinical trial consulting, and clinical pharmacology services. It serves pharmaceutical and medical device companies, and scientific re…
Full company profileR&G PharmaStudies Co. Ltd. A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
R&G PharmaStudies Co. Ltd. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 425M | 484M | 608M | 638M | 721M | 744M | 851M | 952M |
| Gross Profit | 185M | 190M | 233M | 235M | 287M | 276M | 296M | 283M |
| Operating Income | 99.0M | 102M | 120M | 112M | 148M | 130M | 135M | 113M |
| EBITDA | 116M | 124M | 151M | 164M | 218M | 198M | 194M | 113M |
| Net Income | 82.6M | 83.8M | 99.2M | 113M | 163M | 140M | 137M | 100M |
| EPS | 1.84 | 1.16 | 1.38 | 1.18 | 1.69 | 1.45 | 1.42 | 1.04 |
| Balance Sheet | ||||||||
| Total Assets | 447M | 536M | 677M | 1.88B | 2.07B | 2.34B | 2.40B | 2.42B |
| Total Liabilities | 197M | 199M | 240M | 289M | 319M | 500M | 424M | 413M |
| Shareholders' Equity | 238M | 323M | 423M | 1.59B | 1.75B | 1.83B | 1.97B | 2.00B |
| Cash & Short-term Investments | 274M | 294M | 362M | 1.52B | 991M | 1.07B | 1.13B | 1.31B |
| Cash Flow | ||||||||
| Operating Cash Flow | 103M | 44.1M | 115M | 130M | 193M | 155M | 114M | - |
| Capital Expenditure | 26.0M | 25.5M | 38.3M | 20.8M | 19.9M | 20.0M | 19.3M | 17.7M |
| Free Cash Flow | 77.5M | 18.6M | 76.3M | 110M | 173M | 135M | 94.9M | 23.3M |
| Ratios | ||||||||
| ROE | 34.8% | 26.0% | 23.5% | 7.1% | 9.3% | 7.7% | 7.0% | 5.0% |
| ROA | 18.5% | 15.6% | 14.6% | 6.0% | 7.8% | 6.0% | 5.7% | 4.1% |
| Net Profit Margin | 19.4% | 17.3% | 16.3% | 17.8% | 22.5% | 18.8% | 16.1% | 10.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
R&G PharmaStudies Co. Ltd. A dividends
- Dividend yield
- 0.22%
- Forward dividend
- 0.16 CNY
- Payout ratio
- 8.6%
- Ex-dividend date
- Jul 3, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 11.8M | 0.12 | 8.6% |
| 2024 | CNY 28.4M | 0.29 | 20.2% |
| 2023 | CNY 5.82M | 0.06 | 3.6% |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.6:1 on Jun 29, 2023.
Who owns R&G PharmaStudies Co. Ltd. A
- Insiders 60.00%
- Institutions 10.27%
- Public & others 29.73%
- Shares outstanding 96.6M
- Free float 36.6M
R&G PharmaStudies Co. Ltd. A company profile
- Company name
- R&G PharmaStudies Co. Ltd. A
- Ticker
- 301333.SHE
- ISIN
- CNE100005K44
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2,645
- Fiscal year end
- December
- Address
- North Tower, Beijing, China, 100048
- Phone
- 86 10 8801 8650
- Website
- rg-pharma.com
About R&G PharmaStudies Co. Ltd. A
R&G PharmaStudies Co., Ltd. operates as a clinical trial outsourcing service provider in China and internationally. It offers drug clinical research and development integrated services. The company's services include clinical trial operation, clinical trial site management, biological sample testing, data management and statistical analysis, clinical trial consulting, and clinical pharmacology services. It serves pharmaceutical and medical device companies, and scientific research institutions. The company was founded in 2008 and is headquartered in Beijing, China.
R&G PharmaStudies Co. Ltd. A management
7- Mr. Jie Wu M.B.A.Chairman & GM · born 1961
- Ms. Qian ZhaoChief Financial Officer · born 1984
- Ms. Leyan TengCOO, Senior VP & Director · born 1972
- Mr. Wei Wang EMBADeputy GM & Director · born 1978
- Mr. Jigang Li M.B.A.Senior VP & Chief Medical Officer · born 1973
- Dr. Shuqi LiSenior VP, Board Secretary & Director · born 1965
- Lilin ZhaoAccounting Supervisor